Repatha cuts first major cardiovascular event risk by 31% in high-risk diabetes patients without artery plaque.

Amgen's Repatha (evolocumab), when added to statins or other LDL-C lowering treatments, significantly reduced the risk of first major cardiovascular events by 31% in high-risk patients with diabetes but no known significant artery plaque, according to a subgroup analysis from the VESALIUS-CV trial. The study followed 3,655 patients for nearly 5 years and showed Repatha lowered LDL cholesterol to a median of 44 mg/dL, well below levels typically achieved with statins alone. These findings support earlier and more intensive LDL-C lowering to prevent heart disease before plaque buildup occurs. The FDA expanded Repatha's approval in 2025 to include adults at increased cardiovascular risk due to uncontrolled LDL-C, highlighting its growing role in primary prevention.